| First Author | Ahmed T | Year | 2022 |
| Journal | J Biol Chem | Volume | 298 |
| Issue | 9 | Pages | 102297 |
| PubMed ID | 35872017 | Mgi Jnum | J:359023 |
| Mgi Id | MGI:7332142 | Doi | 10.1016/j.jbc.2022.102297 |
| Citation | Ahmed T, et al. (2022) EPDR1 is a noncanonical effector of insulin-mediated angiogenesis regulated by an endothelial-specific TGF-beta receptor complex. J Biol Chem 298(9):102297 |
| abstractText | Insulin signaling in blood vessels primarily functions to stimulate angiogenesis and maintain vascular homeostasis through the canonical PI3K and MAPK signaling pathways. However, angiogenesis is a complex process coordinated by multiple other signaling events. Here, we report a distinct crosstalk between the insulin receptor and endoglin/activin receptor-like kinase 1 (ALK1), an endothelial cell-specific TGF-beta receptor complex essential for angiogenesis. While the endoglin-ALK1 complex normally binds to TGF-beta or bone morphogenetic protein 9 (BMP9) to promote gene regulation via transcription factors Smad1/5, we show that insulin drives insulin receptor oligomerization with endoglin-ALK1 at the cell surface to trigger rapid Smad1/5 activation. Through quantitative proteomic analysis, we identify ependymin-related protein 1 (EPDR1) as a major Smad1/5 gene target induced by insulin but not by TGF-beta or BMP9. We found endothelial EPDR1 expression is minimal at the basal state but is markedly enhanced upon prolonged insulin treatment to promote cell migration and formation of capillary tubules. Conversely, we demonstrate EPDR1 depletion strongly abrogates these angiogenic effects, indicating that EPDR1 is a crucial mediator of insulin-induced angiogenesis. Taken together, these results suggest important therapeutic implications for EPDR1 and the TGF-beta pathways in pathologic angiogenesis during hyperinsulinemia and insulin resistance. |
